June 2026 Research Update

This month added a clearer message that cold agglutinin disease (CAD) and cold agglutinin syndrome (CAS) can look different under the microscope than they look at the genetic level. In a small series, some patients had bone marrow patterns that resembled a lymphoma subtype, but their genetic and antibody-gene patterns still looked more like CAD. This kind of mismatch matters because it points to why some cases are hard to label using appearance alone. [1]

Across the eight patients, the most consistent molecular sign was that many used the same antibody gene (IGHV4-34), which has been linked to CAD in prior work. At the same time, the study did not find two mutations (MYD88 L265P and CXCR4) that are often used to support a diagnosis of lymphoplasmacytic lymphoma, even when the bone marrow looked LPL-like. A few other gene changes were seen in some patients, but there was no single new mutation that explained all cases. [1]

For patients, this is mainly about understanding why the name on a pathology report can be complicated in cold agglutinin disorders, especially when bone marrow findings overlap with lymphoma-like patterns. This study supports the idea that adding molecular testing (looking at antibody genes and selected mutations) may help clarify the underlying condition in some confusing cases, but it does not prove which tests should be done for everyone. Because the report covers only eight people at one center, it is best seen as an early signal that needs confirmation in larger groups. [1]

This month included a real-world snapshot suggesting that cold-type autoimmune hemolytic anemia (CAD/CAS) can come with different risks than warm-type disease. In one Hungarian center, CAD/CAS made up 17% of autoimmune hemolytic anemia cases and tended to involve older patients. The study also reported worse 10-year survival for CAD/CAS than for warm autoimmune hemolytic anemia. [2]

The same report pointed to blood clot events as an important part of the illness burden for some people with cold-type disease. Across the full autoimmune hemolytic anemia cohort, five patients had thromboembolic events. Antiphospholipid antibodies were detected more often in people with CAD/CAS than in those with warm autoimmune hemolytic anemia. The study also described common care approaches in that center, including frequent use of rituximab in CAD patients and the use of preventive blood thinners in selected higher-risk situations. [2]

For patients and caregivers, this adds context about what CAD/CAS can look like across years in a clinic population, including that clotting problems may occur and that long-term outcomes may differ from warm autoimmune hemolytic anemia. It does not show that any one treatment causes better survival, because it was a small, single-center review of past care. Still, it helps set expectations about the kinds of complications and monitoring questions researchers continue to study in CAD/CAS. [2]

This month, case reports highlighted that CAS can appear in very specific settings and sometimes requires urgent, individualized hospital-level care. Across three single-patient reports, CAS was connected to an infection-related trigger (EBV reactivation or Mycoplasma pneumoniae) or to an underlying blood cell clone tracked by a mutation. These reports do not tell how common these situations are, but they show the range of ways CAS can start and the kinds of responses doctors may observe. [3] [4] [5]

In one person with well-controlled HIV who was taking corticosteroids for kidney disease, CAS appeared alongside EBV reactivation measured by a rising EBV DNA level, and the hemolysis improved after rapid steroid tapering and supportive care. This case illustrates a possible link between immune suppression, viral reactivation, and cold-antibody hemolysis, while also showing that the other condition stayed in remission in that patient. [3]

In another report, a young man with Mycoplasma pneumoniae-associated CAS had hemolysis that did not settle with antibiotics alone, and therapeutic plasma exchange was followed by negative antibody screens and improved hemolysis markers. The patient still required many transfusions during the course, but eventually became transfusion independent by day 30. This case helps illustrate plasma exchange as a short-term way to lower harmful antibodies in severe, fast-moving situations. [4]

A separate case report described autologous stem cell transplantation in a person with CAS, where sustained disappearance of a MYD88 p.L265P-mutant clone was observed before the CAS resolved. This links improvement in hemolysis to deeper control of an underlying abnormal B-cell clone in that one patient. Because it is a single case with limited detail provided, it mainly serves as a research observation rather than a general expectation. [5]

For patients, these case reports mainly add understanding rather than changing what is known for most people with CAD/CAS. They show that infection-related triggers and immune suppression can be part of the story for some individuals, and that intensive measures like plasma exchange or stem cell transplantation may be used in unusual or severe situations. What remains uncertain is how often these exact triggers apply, and which patients are most likely to follow a similar course, because each report describes only one person. [3] [4] [5]